The Nomination Committee proposes Professor Anna Martling and Thomas von Koch as new Board members

Report this content

The Nomination Committee of Bactiguard Holding AB (publ) (Bactiguard) proposes to the Annual General Meeting 2019, Professor Anna Martling and Thomas von Koch as new Board members.

Anna Martling is Professor of Surgery and Dean of Campus North at Karolinska Institutet and at the same time Senior Consultant Surgeon in cancer at the Karolinska University Hospital in Stockholm. Anna Martling has a PhD from Karolinska Institutet and broad experience of both clinical work and research, especially in cancer diseases. Anna Martling's research has received multiple awards, among others from the Royal Academy of Sciences and the Swedish Surgical Society. Since 2019, Anna Martling is a member of the Faculty Board at Karolinska Institutet.

Anna Martling has a holding of 823 B shares in Bactiguard.

Thomas von Koch is one of two founders and principal owners of Bactiguard and was chairman of the Board in the period 2005 to 2014. In connection with his appointment as CEO of EQT Partners AB (EQT), Thomas von Koch resigned his assignment on the board of Bactiguard in March 2014. At the end of 2018, he stepped down from the CEO role in EQT and thus freed more room for other assignments.

Thomas von Koch has a Master of Science in Business Administration from the Stockholm School of Economics and has solid experience of board work, investments, structural transactions and strategic alliances in several different industries.

Thomas von Koch has a holding of 2,000,000 A shares and 4,125,878 B-shares in Bactiguard (directly and via companies), corresponding to 18.4 percent of the capital and 34.8 percent of the votes in the company.

The Nomination Committee proposes re-election of the Board members Mia Arnhult, Christian Kinch and Jan Ståhlberg, also to be re-elected as Chairman of the Board. Marie Wickman-Chantereau and Svante Östblom have both declined re-election.

The Nomination Committee's complete proposal will be presented in the notice to the Annual General Meeting 2019 and at the company's website at the same time. 

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2019-04-12, at 14.00

For further information, please contact:
Cecilia Edström, CFO, cell phone: +46 722 262 328

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives on